VC · AI + Biology + HealthcareVenture Capital · AI + Biology + Healthcare
Jeffrey Low, MD
Investing at the intersection of AI, biology, and healthcare
Partner, Averin
Scout Partner, Sequoia Capital
Perspective
Featured Insights
View all →Latest
LinkedIn·
Takeda's Head of R&D Gave an AI Company a Molecule His Team Had Given Up On
Good binder, bad biophysics. The AI company sent back 15 to 20 sequences and a handful worked. Takeda's chemists said traditional methods couldn't have found those changes. Andy Plump on that, and three mistakes he admits on the record.
987 views · 22 engagements
Andreessen Horowitz·
16 Pitfalls to Avoid When Building a Computational Therapeutics Company
LinkedIn·
Biotech Is Crowding Into Consensus at the Wrong Moment
35.8K views · 713 engagements
Portfolio
Select Investments
View all →
Exscientia
AI-driven drug discovery platform combining precision design with automated experimentation.
IPO (NASDAQ: EXAI), merged with Recursion
“Jeffrey is the rare investor who understands both AI and drug discovery. He backed Exscientia early, helped shape our strategy, brought credibility to subsequent financings, and was a valuable partner through our IPO.”
Board Observer·Novo Holdings
Details▾
Erasca
Precision oncology company developing therapies targeting the RAS/MAPK pathway.
IPO (NASDAQ: ERAS)
“Jeffrey and my relationship spans many years, even before Erasca's launch. In the early days of the company's build, Jeffrey was ahead of the curve and was among the early investors to commit. This exemplifies Jeffrey's instinct for finding and backing exceptional teams rather than just following others.”
Investor·Andreessen Horowitz
Details▾
Freenome
Multiomics platform for early cancer detection through routine blood draws.
SPAC (NASDAQ: FRNM)
“I've known Jeffrey since Freenome was a five-person company. He helped lead our Series A, and over the years became one of the closest partners to me and the leadership team. When it mattered most, Jeffrey consistently stepped up well beyond what you'd expect from a typical investor.”
Board Observer·Andreessen Horowitz
Details▾Presence
Recent Appearances
View all →
BFA New Frontier 2026
From Seed to IPO in Biotech
Two sessions at BFA Global Investors' annual US investor conference, both hosted by Jeff Pehl. A biotech fireside chat on why AI's real value lies in better biological and clinical bets rather than faster discovery, with clinical trial design as the nearest prize. Plus a main-track panel with Kristin Baker Spohn of BAM Corner Point on where AI is already paying off in healthcare.
Speaking·
TreeHub Founders Lunch
Company Creation and What Makes a Healthcare Founder Fundable
Fireside chat with founders in TreeHub's health-focused residency: Averin's company creation model, how capital gets metered from validation through launch, and where defensibility breaks for AI-native healthcare companies. Plus what earns conviction in a founding team.
Speaking·
Jefferies London Healthcare Conference 2025
Meeting the Moment in Biopharma Transactions: A Conversation With Leading Executives and Investors Steering Companies Through Uncertainty
Panelist at the Jefferies London Healthcare Conference 2025, joining leading executives and investors in a conversation on navigating biopharma transactions through uncertainty — covering deal strategy, market timing, and the evolving dynamics shaping healthcare M&A and investment.
Speaking·
Key takeaways